Sprout Pharma = Fools Gold

Discussion in 'Valeant Pharmaceuticals' started by anonymous, Sep 24, 2015 at 2:26 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Boeringer Ingelheim is a massive diversified company with huge pockets and a major presence worldwide especially in the EU. Do you really think they would just bail on R&D if they thought this was a blockbuster with worldwide potential ANSWER NO. Without a doubt this is GOING to be the most moronic waste of 1B dollars ANY PHARMA COMPANY HAS EVER MADE


    The FDA first rejected flibanserin in 2010 after a panel of expert advisers unanimously voted against the drug, saying its benefits did not outweigh its risks. The drug's initial developer, Boehringer Ingelheim, abandoned work on the drug in 2011 and sold it to Sprout, a startup headed by a husband-and-wife team from Raleigh, North Carolina.

    Sprout resubmitted the drug with additional effectiveness and safety data, but the FDA again rejected the drug in October 2013
     

  2. anonymous

    anonymous Guest

    That is actually such an accurate description-Fools Gold!
     
  3. anonymous

    anonymous Guest

    Why did a big pharma like Merck,Pfizer,Novartis,GSK not jump on this it make no sense. Ready to launch no R&D and they passed that says it all !
     
  4. anonymous

    anonymous Guest

    Upjohn bailed on pioglitazone and that became a $4 billion product. Viagra was a failed
    Blood pressure med until Pfizer made it an ED drug.
     
  5. anonymous

    anonymous Guest

    Lets face it is clear they did not get the job. This is such a unique opportunity with some risk but it a risk worth taking.
     
  6. anonymous

    anonymous Guest


    LOL risk for the patients who waste their money
     
  7. anonymous

    anonymous Guest

    Anyone know when the sales force will start selling?
     
  8. anonymous

    anonymous Guest

    Never